14490-CDx-homepage-header-1

Accelerating R&D to Commercialization by Leveraging Predictive Biomarkers & Clinical Diagnostics Evidence for Best Patient Outcomes in Target Populations

The 11th World Clinical Biomarkers & CD x Summit returns in 2021 as the only end-to-end industry-led meeting diving deep into the science of transitioning biomarkers to the clinic, their clinical validation and later commercialization with a CDx.

With the increasing sophistication of diagnostic processes and expanding knowledge about association between biomolecules, genomics and acute disease, interest in biomarkers is at an all-time high. As the industry is delivering significant patient benefits, accelerated clinical timelines and healthcare cost savings, now is the time to join with key stakeholders across biomarker, translational, clinical, regulatory and commercial functions to tackle end-to-end challenges and deliver game-changing drug-Dx products to market.

Across 2 days of comprehensive content, we will gather 1000+ precision medicine pioneers online as 70+ global expert speakers share inspiring stories, unpresented data and innovative partnership collaborations to help you overcome your most pressing challenges and accelerate curative medicine.

With three tracks, explore movement within bioanalytical analysis, AI/ML application, data sharing and the regulatory and payer landscape across immune-oncology, neurodegenerative, metabolic, autoimmune and rare indications for a diverse picture of today’s expanding personalized medicine ecosystem.

Join us for an unmissable event, brining you the tools, insights and techniques to design a clinically robust biomarker and commercially competitive CDx!

What’s On?

Returning to a three-tracked format, World CB & CDx is designed to be your organization’s one-stop-shop for end-to-end insights across the spectrum of precision medicines drug development.

Here’s what you can get involved in:

Your Plenary Speakers

Gathered by the aim of getting the best option to the right patient as quickly and efficiently as possible, unite with the 1000+ of your precision medicine peers to explore precision medicine opportunity to treat diverse populations, end-to-end CDx development case studies, latest diagnostic interventions reaching the market and biopharma’s efforts to maximise the utility of data.

Christopher Conn

Director, Companion Diagnostics Strategy Lead

AbbVie

Danielle Murphy

Director, Translational Oncology

Pfizer

Jonathan Levenson

Vice President, Translational Biology

Tiaki Therapeutics

Kashyap Patel

President

Community Oncology

Kaye Foster

Senior Advisor & Executive Coach

The Boston Consulting Group (BCG)

Moving Biomarkers Towards the Clinic Speakers

Support your early biomarker discovery and development through robust analytical validation and effectively validate and translate assays to make the clinical transition. Meet leaders challenging complex disease heterogeneity across immune-oncology, metabolic, autoimmune and neurodegenerative disease with NGS, organoid modelling, multi-omics and comprehensive data collection.

Andrea Stevens

Global CoDx Market Access Director

Janssen Inc.

Brian Baker

Senior Director, Regulatory Affairs (CDx)

Regeneron Pharmaceuticals

Chowdary Dondapati

Executive Director, Head of CDx Marketing (US) VITRAKVI

Bayer Oncology

Eugean Jiwanmall

Senior Research Analyst for Medical Policy & Technology Evaluation

Independence Blue Cross

Katherine Block

Director, Biomarker Sciences

Sangamo Therapeutics

Clinical Biomarker & Assay Development

Draw actionable insights from clinical data to establish an effective trial strategy and inform treatment decisions making an impact in target populations. Showcasing data from small molecules, T-cell therapies, bispecific antibodies and neoantigen studies, and featuring the latest on liquid biopsy and genomic analysis, determine your clinical cut-offs with confidence.

Alessandra Cesano

Chief Medical Officer

ESSA Pharma

David Portman

Chief Executive Officer, Chief Medical Officer

Sermonix Pharmaceuticals

Ellie Corigliano

Head of CDx Cell & Gene Therapies Oncology

GlaxoSmithKline

Jennifer Dacpano- Komansky

Director, Global Regulatory Affairs, Medical Devices

Novartis

Markus Zettl

Senior Director of Immuno–Oncology

Pieris Pharmaceuticals GmbH

Drug-Dx Co-Development

Develop, identify and validate the technologies you need to obtain optimal results from your trials then establish effective internal and external stakeholder collaboration to expedite drug-Dx commercialization whilst optimizing reimbursement. Apply expert practical knowledge to navigate the fast-growing CDx market delving into case studies across oncology in addition to emerging gene therapy and rare disease, and gain a picture of the real-world-evidence and patient perspectives broadening assay adoption.

Arunthi Thiagalingam

Director, Pharmacology/ Translational Medicine

Spectrum Pharmaceuticals

Chris Whelen

Associate Director & Head of Translational Genetics

Biogen

Joshua Xu

Branch Chief, National Center for Toxicological Research

US Food & Drug Administration

Lakshmi Amaravadi

Vice President, Head of Translational Medicine

Boston Pharmaceuticals

Michael Fossel

President & Founder

Telocyte

Featuring exclusive updates on the latest technologies, tools and techniques innovating biomarker-driven drug development, meet our event partners:

Other Events In The Series